

DiagnosTechs™

Clinical & Research Laboratory
Quarterly Newsletter

Articles in this edition

- 1 *Blastocystis: A Question of Pathogenicity*
- 3 *Diagnos-Techs Introduces—*
Matthew Stoner, PhD
Scott Buesing, ND
- 4 *The Therapy Corner: The Anxiety-Depression Spectrum*



Join Diagnos-Techs in Chicago for Digestive Disease Week!

May 4-6
McCormick Place
Chicago, IL

Booth #3516

Register at www.ddw.org

Need assistance with test interpretation? We're here to help!

Call to set up an appointment with a member of our medical support team.

1-800-878-3787




Blastocystis: A Question of Pathogenicity

Carrie C. McMillin, ND

With our growing knowledge of the intricacies of the gut microbiome, we are often faced with difficult questions regarding the clinical implications of this knowledge. Recent improvements in diagnostic methods allow us to more accurately identify which microbes are present; however, as clinicians we need to make the decision to treat or not to treat—a decision that is not always straightforward. Many organisms are not clearly classified as pathogenic or nonpathogenic, resulting in confusion around their clinical significance. One such group of organisms that has been widely disputed is *Blastocystis* spp. There has been considerable discussion regarding its status as a true pathogen and the legitimacy of a disease (blastocystosis) caused by this organism. A review of current literature, however, shows that accumulating evidence strongly suggests that *Blastocystis* is a potentially pathogenic organism.

There are several confounding factors that make it difficult to clearly categorize *Blastocystis*. First of all, humans are host to many different genotypes of *Blastocystis*. The

existence of various genotypes may be the reason for conflicting data,¹⁻³ as it is possible that only some isotypes are pathogenic.⁴ In addition, it is difficult to differentiate among *Blastocystis* isotypes based on morphology. As a result, some studies have employed the use of polymerase chain reaction (PCR) testing to distinguish between various genotypes. In one of the most



Blastocystis cysts.

extensive studies conducted, it was found that among these genotypes, *Blastocystis* can be grouped into seven distinct subtypes,^{5,6} although some sources propose more. It has also been shown that transmission can occur between animals and humans, illustrating that animals can serve as a large potential reservoir for human infections.¹

Historically, there has also been much debate regarding the taxonomic classification of *Blastocystis*. Since its discovery, it has been classified as the cyst of a flagellate, vegetable, yeast, and fungus, only recently having been reclassified as a protist. Today *Blastocystis* is included as a stramenopile, a class of botanical protists such as brown algae that possess flagella with mastigonemes

Blastocystis
continued from front cover.

(hair-like structures projecting from the flagellum). *Blastocystis*, however, is nonmotile and does not possess flagella. A new class for *Blastocystis* was therefore created—*Blastocystea*.^{1,7}

As mentioned earlier, the various *Blastocystis* subtypes can be transmitted between animals and humans in addition to human-human transmission. This makes it difficult to assign *Blastocystis* species according to the host of origin. In fact, this may be one reason for conflicting reports regarding cell variations and pathogenesis in the past. It has been noted in epidemiological studies that subtype 3 is the most frequently isolated. As such, it is widely believed that this is the most likely genotype of human origin, formerly designated as *B. hominis*.⁸⁻¹¹ Because humans can be infected by numerous *Blastocystis* subtypes, and the various subtypes are indistinguishable from each other via microscopy, it is now recommended that laboratories report the presence of *Blastocystis* spp. instead of *Blastocystis hominis*. (Note: This is a change that you will soon see in the Diagnos-Techs microscopy reports.)

Although it can be found worldwide,^{12,13} *Blastocystis* has a higher prevalence rate in developing countries. This has been linked to poor hygiene, contaminated food and water consumption, and exposure to animals.¹⁴ Recent studies point to the classification of *Blastocystis* as pathogenic or opportunistic, concluding that it may be associated with a variety of disorders. It has also been suggested that immunocompromised patients are at greater risk for *Blastocystis*-associated disorders.^{1,15-18}

Interestingly, several surveys have reported that *Blastocystis* was more frequently isolated in immunocompetent individuals suffering from intestinal disorders than similar patients without GI symptoms.¹⁹⁻²³ Another survey pointed out an increased prevalence of *Blastocystis* isolation in atopic patients.²⁴

More recent research has focused on investigating whether the biology and pathogenicity of *Blastocystis* is related to genotype. Unfortunately, no conclusive data has been found. It has, however, been suggested that subtype 1 is associated with disease, while subtypes 2 and 3 appear to be nonpathogenic,¹ although more research is needed.

There is accumulating evidence of an association between *Blastocystis* and irritable bowel syndrome (IBS).


Blastocystis-associated illness is most commonly associated with abdominal pain and acute or chronic diarrhea, although it has also been linked to nausea, vomiting, bloating, flatulence, and anorexia.^{1,25} Diagnosis is made by microscopic stool examination (O&P testing), ideally conducted on fecal samples from three separate days.²⁶ There is some evidence that the acute GI presentations are associated with an increased infection density, most commonly greater than five parasites per high power field.^{1,16,19} Other signs and symptoms include eosinophilia,²⁷

fecal leukocytes,²⁸ and cutaneous rashes (with urticaria being most notable).²⁹ In general, *Blastocystis* is non-invasive,³⁰ with extraintestinal infections being a rare occurrence and only then when mediated by another pathogen. It has also been noted that mixed infections with *Blastocystis* and *Entamoeba histolytica* are not uncommon.³¹ There is accumulating evidence of an association between *Blastocystis* and irritable bowel syndrome (IBS). Specifically, some studies have shown an increased prevalence of *Blastocystis* in patients with IBS compared to IBS-negative patients with GI symptoms.^{32,33} It is not yet clear whether *Blastocystis* can be considered an etiological agent of IBS or IBS simply creates an environment in which *Blastocystis* can thrive.³⁴

As with many other organisms, clinical outcomes of the presence of *Blastocystis* vary considerably based on numerous factors, making it difficult to predict its pathogenic potential. Some studies have shown that treatment with metronidazole,³⁵ nitazoxanide,³⁶ and trimethoprim-sulfamethoxazole (TMP-SMX)³⁷ has resulted in eradication of the organism and resolution of GI symptoms. However, these drugs are all broad-spectrum antibiotics; therefore, it is difficult to ascertain if clinical cure was instead the result of treatment and eradication of a separate and unidentified pathogenic organism.

Some herbs that have been found to reduce or inhibit growth of *Blastocystis* spp. include *Coptis chinensis*, *Brucea javanica*, *Punica granatum*, *Picrorhiza scrophulariiflora*, and *Allium sativum*.³⁸⁻⁴² In one study, children treated with *Saccharomyces cerevisiae* had a higher cure rate than

those receiving metronidazole.⁴³ It has also been suggested that a high fiber, low lactose diet may be an important component to a *Blastocystis* treatment plan.

Despite considerable gaps in our understanding of this organism, it is worth noting that there are no studies to date that prove unequivocally that *Blastocystis* is nonpathogenic, and there is accumulating evidence around its pathogenic potential. Treatment should be considered for both acute and chronic cases in the presence of associated symptoms, appropriate clinical context, and the absence of other causative pathologies. 

For references, please see Newsletter section of website (www.diagnotechs.com).



Upcoming Free Webinars:

**April 10th, 2014 –
Clinical Update -
Inflammatory Bowel Disease**

**May 15th, 2014 –
Clinical Update - Celiac
Disease**

Please visit www.diagnotechs.com for more information about our free webinars.



Diagnos-Techs Introduces—

Matthew Stoner, PhD

Director of Research and Development



Dr. Stoner completed his PhD in Toxicology at Texas A&M University, where he studied estrogen receptor-modulated

gene expression in breast cancer and endometrial cancer. He subsequently completed postdoctoral training in Molecular Toxicology at the Pennsylvania State University. Dr. Stoner then was appointed Research Assistant Professor in the College of Pharmacy at the University of Rhode Island, where he established a research laboratory supported by the Rhode Island IDEa Network of Biomedical Research

Excellence. Additionally, while at the University of Rhode Island, he lectured in the areas of endocrinology and laboratory techniques in molecular biology and trained and mentored junior scientists. Most recently, Dr. Stoner was Senior Research Scientist at CertiChem, Inc., where he optimized sensitive bioassays for the detection of endocrine-active chemicals that leach from consumer products. He has more than 20 peer-reviewed publications in journals that cover diverse areas of cell and molecular biology and toxicology. As the Director of Research and Development at Diagnos-Techs, Dr. Stoner investigates and incorporates into production new technologies and methodologies to expand our clinical diagnostic test offerings.

Scott Buesing, ND

Medical Support



After receiving a Bachelor's degree in Electrical Engineering from Iowa State University, Dr. Buesing went on to acquire a Doctorate in

Naturopathic Medicine from Bastyr University in 2004. While in school, Dr. Buesing received an NIH research training grant to study the in-vitro effects of an alternative cancer treatment from the 1930s. Upon graduation, he collaborated on several research studies at Bastyr University including benefits of creatine and diets high in legumes. In 2008, after several

years in private practice, he joined a multidisciplinary team in a partial hospitalization program for patients suffering with mental health conditions, focusing on integrative treatment. Dr. Buesing utilized treatments including dietary and lifestyle changes, oral and intravenous nutrient therapies, botanical medicine, biofeedback, mind-body techniques, and meditation. While in practice, he taught patient-oriented classes in meditation and nutrition. In addition to clinical practice, Dr. Buesing has worked as a consultant, providing synopses of current medical research on numerous health topics including vitamin D and healthy dietary strategies.



The Therapy Corner

The Anxiety-Depression Spectrum

Brandy Webb, ND

Anxiety disorders make up the largest category of psychiatric conditions in the United States, with depressive mood disorders following second (with lifetime prevalence rates of 28% and 16%, respectively).¹ A growing number of patients present to the doctor's office in search of treatment for generalized anxiety as they discover they are unable to manage the incessant worry, insomnia, and accompanying physical symptoms they experience on a near-daily basis. Individuals with known psychiatric disorders are not the only ones affected—one in three individuals will suffer a panic attack at some point in his or her lifetime.² Depressive symptoms may be less common, but they are no less pernicious to a patient's quality of life; this is particularly true of the persistent thoughts of worthlessness, apathy, and debilitating fatigue. What's more, over 70% of individuals with either anxiety or depression meet the diagnostic criteria for both conditions; thus, it is very likely that you will encounter patients suffering from anxiety and depression simultaneously.³

Clinical Features & Diagnosis

Generalized anxiety disorder (GAD), the most common anxiety disorder, is characterized by excessive worrying that causes significant impairment and occurs on more days than not for at least six months. When screening for GAD, the single best question to ask is,

"Do you worry excessively about minor matters?" The World Health Organization's ICD-10 description calls this "free-floating" anxiety. Generalized anxiety disorder is diagnosed through careful psychiatric assessment and only after other psychiatric conditions (such as ADHD, depression, and bipolar disorder) and organic diseases have been ruled out. The psychiatric evaluation should include questions about possible substance abuse, personal history of trauma (emotional, physical, or sexual), and family psychiatric history. Anxiety symptoms can be related to underlying conditions like thyroid disease, anemia, and cardiac conditions. In patients with clinical features that may suggest these or other organic diseases, the minimum work-up should include a physical exam as well as a CBC, chemistry panel, thyroid panel, circadian cortisol assessment (such as the TAP or ASI available through Diagnos-Techs), and ECG. If drug abuse is suspected, toxicology testing should be performed as well. Additional factors to consider include caffeine intake, nicotine use, and prescription medications.

While there may be some overlap with anxiety, patients experiencing depressive disorders primarily suffer from hopelessness, depressed mood, and apathy toward activities that previously brought joy. The hallmark for depression is that these symptoms last a minimum of 2-4 weeks and cause significant distress

to the patient. As with anxiety, depressed patients should receive psychiatric screening, a medication review, and laboratory testing to rule out organic disease (CBC, ferritin, chemistry panel, circadian cortisol assessment, thyroid panel, inflammatory markers, and infectious disease testing are all worth considering). Zinc and folate status should be considered in patients presenting with depression or anxiety, as well, due to an apparent association between deficiency in zinc or folate and the development of mood disorders.⁴

Once alternative psychiatric diseases and organic diseases are ruled out, treatment targeting the anxiety or depression (or both) may be pursued.

Conventional Treatment

Cognitive behavioral therapy (CBT) and pharmacologic agents are the mainstays of treating anxiety and depression conventionally. Cognitive behavioral therapy is best facilitated by well-trained professionals, usually a certified mental health counselor or psychiatrist, although many primary care and holistic practitioners incorporate some degree of CBT into their practices. This type of therapy involves a combination of identifying and modifying destructive thought patterns, emotions, and behaviors that contribute to specific psychiatric states like anxiety or depression. Therapists play an active role guiding patients through self-reflection and cognitive/behavioral exercises that attempt to change certain automatic processes that predispose to anxiety or depression. For example, a cognitive behavioral therapist might help an anxious patient prone to

irrational fears recognize that when she feels her heart beating hard in her chest, she should refrain from concluding that she is having a heart attack. Cognitive behavioral therapy has demonstrated reduced relapse rates after a course of treatment compared to drug therapy.^{5,6} Nonetheless, for a variety of reasons, many patients are managed with drug interventions.

The choice of pharmacotherapy depends on the particular presenting complaints and the severity of symptoms. The drug therapies employed for moderate-to-severe anxiety and depression are generally the same. For mild depression or anxiety, drug therapy is typically not recommended (instead, cognitive behavioral therapy is considered the best conventional approach). For moderate anxiety or depression, CBT and drug therapy are often recommended concomitantly. A psychiatric referral is common at this stage, since these practitioners can facilitate both pharmacotherapy and cognitive behavioral therapy. Initial drug therapy usually involves selective serotonin reuptake inhibitors (SSRIs). This class contains drugs like escitalopram (Lexapro), fluoxetine (Prozac), paroxetine (Paxil), and sertraline (Zoloft). The comparative efficacy of the various SSRIs has been shown to be about the same, although it is worth noting that neither fluoxetine nor sertraline is approved for generalized anxiety disorder (though both are approved for other anxiety disorders and are frequently prescribed for the off-label treatment of GAD).⁷ Thus, choosing which SSRI to use should be guided by factors such as other medications the patient may be taking (due

to risk of known interactions), cost, and potential side effects. For example, escitalopram is less associated with sexual dysfunction compared to other SSRIs, paroxetine is associated with more weight gain compared to other SSRIs, and fluoxetine and sertraline are more associated with sleep disturbances compared to other SSRIs.⁸ Sample adult SSRI initial dosing regimens include the following (for pediatric dosing, please see manufacturer recommendations for each drug):⁷

- Escitalopram (Lexapro) 10mg QD, or
- Paroxetine (Paxil) 20mg QD, or
- Sertraline (Zoloft) 50mg QD

Other classes of psychotropics that are frequently used for initial treatment include serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin modulators, atypical antidepressants, and benzodiazepines. Alternatives like tricyclic antidepressants, monoamine oxidase inhibitors, and antipsychotics are generally

not used for initial treatment due to potential side effects and safety concerns. If initial SSRI treatment fails, first switch to a different SSRI. If the patient still does not respond, consider the following:⁷

- Duloxetine (Cymbalta) 30mg QD, or
- Bupropion (Wellbutrin) 150mg QD (for use in depression but not anxiety)
- L-methylfolate (Deplin) 7.5 or 15mg QD (off-label usage as monotherapy or adjunctive therapy)⁹

For some patients, the pharmacologic approach can be effective at reducing their symptoms of anxiety or depression. For others, however, pharmacotherapy proves ineffective or is associated with significant side effects prompting discontinuation. For these patients, natural approaches to mood stabilization may be a viable alternative to drug therapy.

Continued on page 6.

Anxiety-Depression
continued from page 5.

Natural Treatments

Many patients present to holistic practitioners seeking alternatives to drug therapies for a variety of reasons, such as failure to respond, side effects, or concerns for long term safety. Potential treatments include diet and lifestyle modification, breathing exercises, nutrient therapies, and herbal medicine.

Breathing Exercises

One often-overlooked contributor to anxiety is disordered breathing patterns. It is not always clear why patients develop disordered breathing, although chronic stress may be one contributing factor.¹⁰ Patients affected by this condition often develop chronic hyperventilation syndrome, which is characterized by reduced carbon dioxide levels in the blood. Generally, disordered breathing is not evident to the patient or providers, although one clue is frequent sighing or yawning. In some cases, labs reveal low-normal or depressed serum CO₂; however, capnometry (measuring CO₂ in exhaled air) is the best way to definitively diagnose disordered breathing patterns. Along with a feeling of anxiousness, acute hyperventilation episodes can be associated with palpitations, numbness, tingling of the extremities, lightheadedness, dizziness, and what patients might describe as “air hunger”. Hyperventilation syndrome is more common in females and often becomes worse premenstrually and during pregnancy.¹¹ Blood sugar fluctuations may trigger disordered breathing, as well.¹²

One effective way to treat anxiety is by correcting disordered breathing patterns through breathing exercises. There are numerous breathing exercise techniques, one of which is called the Chaitow technique. This technique involves a 2-3 second inhalation through the nose, followed by a 1-second pause, and ending with a 6-7 second exhalation through lightly pursed lips.¹⁰ Patients should work up to 30 cycles (about five minute’s worth) and perform a full set in the morning, evening, and at times of acute anxiety.

Check out the archived webinar titled “A Neuroendocrine Approach to Anxiety and Depression”.

Dietary Modification

As mentioned, blood sugar fluctuations can trigger disordered breathing, which may predispose to anxiety states. Altered blood sugar metabolism can also play a role in depressive symptoms. A diet comprised primarily of foods with lower glycemic indices, when accompanied by abundant intake of healthy fats, lean protein, and fiber, can lead to improved blood sugar regulation. This can be a key factor in mood stabilization, regardless of where patients fall on the mood spectrum. Often times the challenge is simply getting patients to eat regularly. Reduced appetite is a common symptom in anxiety and depression, and patients may have a tendency to skip meals altogether. Encouraging patients to identify ways

to consume consistent, healthful meals can be a simple, effective intervention in treating these conditions.

Exercise

Another lifestyle modification that can support proper mood balance is physical activity. While not all studies agree, there are promising results suggesting that exercise is beneficial for depression and anxiety in sedentary patients.^{13,14} In fact, exercise recommendations are incorporated into the formal practice guidelines of numerous medical authorities, including the National Institutes of Health and the American Psychiatric Association. Exercise recommendations vary, but a typical regimen consists of 3-5 sessions per week, each session lasting 45-60 minutes, comprised of both aerobic activity and resistance training. Aerobic activity intensity should fall in the 50-85% of maximum heart rate range, while resistance training should consist of, for each targeted muscle group, three sets of eight reps at 80% maximum weight.^{15,16}

Sleep

Anxiety and depression are frequently characterized by sleep disturbances, although it may be difficult to identify clearly which occurred first—the disordered mood or the disordered sleep. Regardless, the association between sleep and mood is well established. Insomnia amplifies the tendency to mistake benign stimuli as threatening, as experienced in anxiety states, and it also can predispose to feelings of hopelessness, as seen in depression.^{17,18} One way to address anxiety and depression is to guide your patients toward improved quality and quantity of sleep, while

also ruling out conditions that might interfere with sleep, such as restless leg syndrome or sleep apnea. The ideal sleep pattern for most individuals consists of eight hours of uninterrupted sleep adhering as much as possible to the natural circadian rhythm (10pm-6am).

Nutrient Therapy & Botanical Medicine

One well established, effective nutrient that can be used in the treatment of both anxiety and depression is 5-hydroxytryptophan (5-HTP). This derivative of the amino acid L-tryptophan is a precursor to serotonin and can be useful for increasing central serotonin levels and thus stabilizing mood. Dosing 5-HTP with L-tyrosine, another amino acid, can result in even greater antidepressant effects.¹⁹ It is important to rule out bipolar disorder and suicide ideation, however, as 5-HTP should be avoided in these patients due to evidence of increased suicide attempts when these individuals take 5-HTP.²⁰ For maximum benefit, 5-HTP should be dosed around 50-100mg TID. Caution is advised when combining with other antidepressants that potentiate serotonin levels (such as SSRIs), as this may result in elevated serotonin levels (a potentially life-threatening condition called serotonin syndrome characterized by blood pressure changes, agitation, and diarrhea).²¹


Piper methysticum (kava) and *Hypericum perforatum* (St. John's wort) are two of the most powerful herbs to treat anxiety and depression, respectively. In fact, although we primarily think of using *Piper methysticum* to treat anxiety, it can be used for depression as well.

Compounds in this herb are thought to bind GABA receptors within the amygdala and hippocampus, which is likely responsible for its mood benefits; at the same time, these compounds appear to inhibit calcium channels, providing skeletal and smooth muscle relaxation.^{22,23} A typical dosing regimen of *Piper methysticum* for anxiety is 70mg TID of a standardized extract (30% kavalactone content). Current evidence suggests that *Hypericum perforatum* targets depression primarily by acting on GABA and benzodiazepine receptors, although it also affects serotonin, norepinephrine, and dopamine pathways.^{24,25} Dosing generally falls within the range of 300mg BID-TID of a standardized extract (0.3% hypericin content). As with 5-HTP, caution should be taken with patients already taking antidepressant drugs, due to the potential for serotonin syndrome with concomitant dosing of *Hypericum perforatum*.²⁶


The following is a summary of the potential natural therapies discussed:

- Chaitow breathing exercises 5 minutes BID
- Low glycemic diet with ample healthful fats, protein, and fiber
- Exercise 3-5 times per week, 45-60 minutes per session
- 8 hours uninterrupted sleep (ideally 10pm-6am)
- For anxiety—*Piper methysticum* 70mg TID standardized extract
- For depression—*Hypericum perforatum* 300mg BID-TID standardized extract
- For anxiety or depression—5-Hydroxytryptophan 50-100mg

TID (for depression, may use in combination with L-tyrosine up to 500-1000mg QD divided dosing)

For more details on natural treatments, please check out the archived Diagnos-Techs webinar titled “A Neuroendocrine Approach to Anxiety and Depression” from January 2014 located at our website (www.diagnostechs.com). In addition to targeting mood disorders directly, it may be important to identify contributing factors pertaining to adrenal function, GI status, and sex hormone levels. Natural therapies to regulate cortisol output, balance gut microbiota, or optimize sex hormones can be beneficial in patients presenting with anxiety or depression, since symptoms may be exacerbated by these other conditions. Thus, treatment plans for patients presenting with mood disorders may include things like fish oil, anti-inflammatory herbs, liver supportive herbs, B-vitamins, zinc, folate, and magnesium. By approaching anxious or depressed patients from a holistic, systems-based approach, practitioners are ensured the greatest likelihood of clinical success. 

For references, please see Newsletter section of website (www.diagnostechs.com).



Issue #17 Chronobiology Letter is published quarterly by Diagnos-Techs Laboratory, Inc. in Kent, WA, USA as an educational resource for our healthcare clients. The content in this newsletter is for informational purposes only and is not to be construed as medical advice.

Diagnos-Techs™, Inc.
19110 66th Avenue S.
Building G
Kent, WA 98032 USA



DiagnosTechs™

THE LEADING LAB IN SALIVA TESTING SINCE 1989

19110 66th Avenue South, Building G
Kent, Washington 98032 USA

www.diagnostechs.com



Client Services

Tips for Success

- Have your **account number** or **accession number** ready before you call.
- **Sign up to access results online.** Call Client Services at **1-800-878-3787** for your password.
- **Please advise patients** to consult with you if they have questions regarding their medications or test results. Medical Support is available for provider questions about medications, results, treatment suggestions, and test recommendations at **1-800-878-3787**.



Courtesy Service

From our Team of Insurance Specialists

Our dedicated team of insurance specialists is trained to assist you with insurance-related questions. We avoid payment processing challenges by helping you and your patients navigate the maze of test codes and fees.



Contact Us

Business Hours

6:30am–5:00pm
Pacific Standard Time (PST)
Monday through Friday,
except major holidays

1-800-878-3787

Lab Address

Sample Processing
6620 S. 192nd Place, Building J-106
Kent, WA 98032 USA



Please visit us online at
www.diagnostechs.com

www.facebook.com/diagnostechs



Free UPS Return Shipping on returned DOMESTIC test kits

Storage & Mailing Instructions for All Specimens

- Ship samples on the same day as last sample collection (preferred).
- If not possible, refrigerate samples and ship within three days. **No ice bags** are required during shipping.
- Write the patient's name and address on the outside of the box.
- Include all samples, test form and, if applicable, a check or a copy of the front and back of insurance card. Please be sure to seal the box with clear tape OR the UPS shipping label (U.S. only).
- **US Domestic:** Deliver completed test kit box to any **UPS** location. **www.ups.com/dropoff** Return shipping to Diagnos-Techs™ is **PRE-PAID**. Kits will arrive within three business days of shipment.



- **International:** Delivery charges apply. Visit our website for access to discounted return shipping via UPS. Deliveries can also be made Monday through Friday via a private courier of your choice.

International deliveries should be addressed to the physical address only, as noted to the right.

Do not address to the PO Box.

International Courier Shipping
Diagnos-Techs™, Inc.
Sample Processing
6620 S. 192nd Pl., #J-106
Kent, WA 98032
p 425-251-0596

ChronoBiology References

Spring 2014—Issue 17

Blastocystis: A Question of Pathogenicity

Carrie C. McMillin, ND

1. Tan K. New Insights on Classification, Identification, and Clinical Relevance of Blastocystis spp. *Clin Microbio Rev.* 2008;21(4):639.
2. Abe, N. Molecular and phylogenetic analysis Blastocystis isolates from various hosts. *Ver Parasitol.* 2004;20:235-242.
3. Noel C, Dufernes F, Gerbod D, et al. Molecular phylogenies of Blastocystis isolates from different hosts: implications for genetic diversity, identification of species, and zoonosis. *J Clin Microbiol.* 2005;43:348-355.
4. Clark C. Extensive genetic diversity in Blastocystis hominis. *Mol Biochem Parasitol.* 1997;87:79-83.
5. Huang D, White A. An updated review on Cryptosporidium and Giardia. *Gastroenterol Clin N Am.* 2006;35:291-314.
6. Kuhls T, Mosier D, Crawford D, Griffis J. Seroprevalence of cryptosporidial antibodies during infancy, childhood, and adolescence. *Clin Infect Dis.* 1994;18:731-735.
7. Cavalier-Smith T. A revised six-kingdom system of life. *Biol Rev Camb Philos Soc.* 1998;73:203-266.
8. Böhm-Gloning B, Knobloch J, Walderich B. Five subgroups of Blastocystis hominis from symptomatic and asymptomatic patients revealed by restriction site analysis of PCR-amplified 16S-like rDNA. *Trop Med Int Health.* 1997;2:771-778.
9. Kaneda Y, Horiki N, Cheng X, et al. Ribodemes of Blastocystis hominis isolated in Japan. *Am J Trop Med Hyg.* 2001;65:393-396.
10. Wong K, Ng G, Lin R, et al. Predominance of subtype 3 among Blastocystis isolates from a major hospital in Singapore. *Parasitol Res.* 2008;102:663-670.
11. Yoshikawa H, Wu Z, Howe J, et al. Polymerase chain reaction-based genotype classification among human Blastocystis hominis populations isolated from different countries. *Parasitol Res.* 2004;92:22-29.
12. Jelinek T, Peyerl G, Löscher T, et al. The role of Blastocystis hominis as a possible intestinal pathogen in travelers. *J Infect.* 1997;35:63-66.
13. Tan K. Blastocystis in humans and animals: new insights using modern methodologies. *Vet Parasitol.* 2004;126:121-144.
14. Blastocystis spp. FAQs. Centers for Disease Control and Prevention Website. <http://www.cdc.gov/parasites/blastocystis/faqs.html>. Updated January 6, 2012. Accessed February 3, 2014.
15. Brites C, Barberino M, Bastos M, et al. Blastocystis hominis as a potential cause of diarrhea in AIDS patients: a report of six cases in Bahia, Brazil. *Braz J Infect Dis.* 1997;1:91-94.
16. Cirioni O, Giacometti A, Drenaggi D, et al. Prevalence and clinical relevance of Blastocystis hominis in diverse patient cohorts. *Eur J Epidemiol.* 1999;15:389-393.
17. Gassama A, Sow P, Fall F, et al. Ordinary and opportunistic enteropathogens associated with diarrhea in Senegalese adults in relation to human immunodeficiency virus serostatus. *Int J Infect Dis.* 2001;5:192-198.
18. Noureldin M, Shaltout A, El Hamshary E, Ali M. Opportunistic intestinal protozoal infections in immunocompromised children. *J Egypt Soc Parasitol.* 1999;29:951-961.
19. El-Shazly A, Abdel-Magied A, El-Beshbishi S, et al. Blastocystis hominis among symptomatic and asymptomatic



- individuals in Talkha Center, Dakahlia Governorate, Egypt. *J Egypt Soc Parasitol*. 2005;35:653-666.
20. Graczyk T, Shiff C, Tamang L, et al. The association of Blastocystis hominis and Endolimax nana with diarrheal stools in Zambian school-age children. *Parasitol Res*. 2005;98:38-43.
 21. Kaya S, Cetin E, Aridogan B, et al. Pathogenicity of Blastocystis hominis, a clinical reevaluation. *Turkiye Parazitoloj Derg*. 2007;31:184-187.
 22. Leelayoova S, Rangsin R, Taamasri P, et al. Evidence of waterborne transmission of Blastocystis hominis. *Am J Trop Med Hyg*. 2004;70:658-662.
 23. Miller S, Rasario C, Rojas E, Scorza J. Intestinal parasitic infection and associated symptoms in children attending day care centres in Trujillo, Venezuela. *Trop Med Int Health*. 2003;8:342-347.
 24. Özcakir O, Güreser S, Ergüven S, et al. Characteristics of Blastocystis hominis infection in a Turkish university hospital. *Turkiye Parazitoloj Derg*. 2007;31:277-282.
 25. Diseases and Conditions: Blastocystis hominis infection. Mayo Clinic website. <http://www.mayoclinic.org/diseases-conditions/blastocysts-hominis/basics/definition/con-20026572>. Published January 25, 2013. Accessed February 3, 2014.
 26. Blastocystis hominis. Stanford University website. http://www.stanford.edu/group/parasites/ParaSites2010/Delamon_Alfredo_Rego/paraSITEfinalweb.htm. Published Unknown. Accessed February 3, 2014.
 27. Garavelli P. The therapy of blastocystosis. *J Chemother*. 1991;3(Suppl 1):245-246.
 28. Diaczok B, Rival J. Diarrhea due to Blastocystis hominis: an old organism revisited. *South Med J*. 1987;80:931-932.
 29. Armentia A, Medez J, Gomez A, et al. Urticaria by Blastocystis hominis. Successful treatment with paromomycin. *Allergol Immunopathol*. 1993;21:149-151.
 30. Chen T, Chan C, Chen H, et al. Clinical characteristics and endoscopic findings associated with Blastocystis hominis in healthy adults. *Am J Trop Med Hyg*. 2003;69:213-216.
 31. Hu K, Lin C, Wang T, et al. Amoebic liver abscess or is it? *Gut*. 2008;57:627,683.
 32. Giacometti A, Cirioni O, Fiorentini A, et al. Irritable bowel syndrome in patients with Blastocystis hominis infection. *Eur J Clin Microbiol Infect Dis*. 1999;18:436-439.
 33. Yakoob J, Jafri W, Jafri N, et al. Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. *Am J Trop Med Hyg*. 2004;70:383-385.
 34. Udkow M, Markell E. Blastocystis hominis: prevalence in asymptomatic versus symptomatic hosts. *J Infect Dis*. 1993;168:242-244.
 35. Nigro L, Larocca L, Massarelli L, et al. A placebo-controlled treatment trial of Blastocystis hominis infection with metronidazole. *J Travel Med*. 2003;10:128-130.
 36. Rossignol J, Kamil S, Said M, et al. Effect of nitazoxanide in persistent diarrhea and enteritis associated with Blastocystis hominis. *Clin Gastroenterol Hepatol*. 2005;3:987-991.
 37. Ok U, Girginkardesler N, Balcioglu C, et al. Effect of trimethoprim-sulfamethaxazole in Blastocystis hominis infection. *Am J Gastroenterol*. 1999;94:3245-3247.
 38. Hawrelak, J. Session Six Notes: Blastocystis. Health Masters Live: The Natural Gastrointestinal Masterclass. Jan 2014. <http://www.healthmasterslive.com/product/the-natural-gastrointestinal-masterclass>.
 39. Yang L, Singh M, Yap E, et al. In vitro response of Blastocystis hominis against traditional Chinese medicine. *Journal of Ethnopharmacology*. 1996;55:35-42.
 40. Su S, Chen G, Zhang R, et al. The Trichomonocidal Effect of Nine Chinese Herbs on the Blastocystis hominis. *Lishizhen Medicine and Materia Medica Research*. 2007;03.
 41. Zhang X, Qiao J, Zhang R, et al. In vitro antiprotozoal effects of Brucea javanica, Coptis chinensis, Radix pulsatillae and Arecae on Blastocystis hominis. *Journal of Tropical Medicine*. 2007;11.
 42. Yakoob J, Abbas Z, Beg MA, et al. In vitro sensitivity of Blastocystis hominis to garlic, ginger, white cumin, and black pepper used in diet. *Parasitology Research*. 2011;109:379-385.
 43. Dinleyici EC, Eren M, Dogan N, et al. Clinical efficacy of Saccharomyces boulardii or metronidazole in symptomatic children with Blastocystis hominis infection. *Parasitology Research*. 2011;108:541-545.
 44. Versalovic J. Manual of Clinical Microbiology. 3rd ed. Washington, DC: American Society for Microbiology Press; 2011.
 45. McHardy I, Wu M, Shimizu-Cohen R, et al. Detection of Intestinal Protozoa in the Clinical Laboratory. *J Clin Microbiol*. 2014;52(3):712.
 46. Tille P. Bailey & Scott's Diagnostic Microbiology. 13th ed. St. Louis, MO: Elsevier Mosby; 2014.



The Therapy Corner: The Anxiety-Depression Spectrum

Brandy Webb, ND

1. Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distribution of DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry*. 2005;62(6):593.
2. Kayton W, Ciechanowski P. Panic disorder: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis. UpToDate.com. Aug 2013.
3. Lamers F, van Oppen P, Comijs HC, et al. Comorbidity patterns of anxiety and depressive disorders in a large cohort study: the Netherlands Study of Depression and Anxiety (NESDA). *J Clin Psychiatry*. 2011 Mar;72(3):341-8.
4. Cope EC, Levenson CW. Role of zinc in the development and treatment of mood disorders. *Curr Opin Clin Nutr Metab Care*. 2010 Nov;13(6):685-9.
5. American Psychiatric Association: Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. <http://psychiatryonline.org/guidelines.aspx> (Accessed on April 17, 2012).
6. Parikh SV, Segal ZV, Grigoriadis, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. II. Psychotherapy alone or in combination with antidepressant medication. *J Affect Disord*. 2009;117 Suppl 1:S15.
7. Gartlehner G, Hansen RA, Morgan LC, et al. Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis. *Ann Intern Med*. 2011 Dec;155(11):772-85.
8. Katon W, Ciechanowski P. Unipolar major depression in adults: choosing initial treatment. UpToDate. Feb 2014.
9. Young SN. Folate and depression--a neglected problem. *J Psychiatry Neurosci*. 2007 Mar;32(2):80-2.
10. Chaitow L, Bradley D, Gilbert C. *Multidisciplinary Approaches to Breathing Pattern Disorders*. Churchill Livingstone. 2002.
11. Damas-Mora J, Davies L, Taylor W, Jenner FA. Menstrual respiratory changes and symptoms. *Br J Psychiatry*. 1980 May;136:492-7.
12. Chaitow L. Breathing pattern disorders, motor control, and low back pain. *Journal of Osteopathic Medicine*. 2004;7(1):34-41.
13. Lee H, Ohno M, Ohta S, Mikami T. Regular moderate or intense exercise prevents depression-like behavior without change of hippocampal tryptophan content in chronically tryptophan-deficient and stressed mice. *PLoS One*. 2013 Jul 4;8(7):e66996.
14. Herring MP, O'Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. *Arch Intern Med*. 2010;170(4):321.
15. Katon W. Unipolar major depression in adults: Choosing initial treatment. UpToDate. Jan 2014.
16. Rethorst CD, Trivedi MH. Evidence-based recommendations for the prescription of exercise for major depressive disorder. *J Psychiatr Pract*. 2013 May;19(3):204-12.
17. Goldstein AN, Greer SM, Saletin JM, et al. Tired and apprehensive: anxiety amplifies the impact of sleep loss on aversive brain anticipation. *J Neurosci*. 2013 Jun 26;33(26):10607-15.
18. Sadler P, McLaren S, Jenkins M. A psychological pathway from insomnia to depression among older adults. *Int Psychogeriatr*. 2013 Aug;25(8):1375-83.
19. van Praag HM. In search of the mode of action of antidepressants: 5-HTP/tyrosine mixtures in depression. *Adv Biochem Psychopharmacol*. 1984;39:301-14.
20. Meltzer HY, Perline R, Tricou BJ, et al. Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders. II. Relation to suicide, psychosis, and depressive symptoms. *Arch Gen Psychiatry*. 1984 Apr;41(4):379-87.
21. Ma Z, Zhang G, Jenney C, et al. Characterization of serotonin-toxicity syndrome (toxidrome) elicited by 5-hydroxy-L-tryptophan in clorgyline-pretreated rats. *Eur J Pharmacol*. 2008 Jul 7;588(2-3):198-206.
22. Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. *Psychopharmacology*. 1994 Dec;116(4):469-474.
23. Martin HB, McCallum M, Stofer WD, Eichinger MR. Kavain attenuates vascular contractility through inhibition of calcium channels. *Planta Med*. 2002 Sep;68(9):784-9.
24. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. *Pharmacopsychiatry*. 1997 Sep;30 Suppl 2:108-12.



25. Müller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. *Pharmacopsychiatry*. 1997 Sep;30 Suppl 2:102-7.
26. Waksman JC, Hard K, Jolliff H, et al. Serotonin syndrome associated with the use of St. John's wort (*hypericum perforatum*) and paroxetine. *J Toxicol Clin Toxicol*. 2000;38(5):521.

